Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock. (VICEPAC)
Cardiac Arrest
About this trial
This is an interventional treatment trial for Cardiac Arrest
Eligibility Criteria
Inclusion Criteria: patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min; and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg. Exclusion Criteria: nclusion criteria: patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min; and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg. Exclusion criteria: minor or pregnant women; OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc.); interval between OHCA and randomization > 6 hours; extracorporeal circulatory assistance requirement in the first 4 hours after OHCA; history of urolithiasis, oxalate nephropathy or hemochromatosis; glucose-6-phosphate deshydrogenase deficiency; nephrolithiasis, hyperoxalyurie patients already treated with vit-C; known vit-C deficit; inclusion in another study; pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min); treatment limitationsor moribound Patient with derpived freedom or with legal protective measures. Patient not covered by French national health insurance
Sites / Locations
- Centre Hospitalier Universitaire d'Amiens
- Centre Hospitalier Béthune
- Centre Hospitalier de Dieppe
- GHEF Site Marne La Vallée
- Centre Hospitalier de LENS
- Centre Hospitalier Universitaire de LILLE
- Centre Hospitalier de Rouen
- Centre Hospitalier Toulon La Seyne sur Mer
- Centre Hospitalier de Valenciennes
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Control group
Experimental group
- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.